MapLight Therapeutics Files for IPO, Led by Morgan Stanley, Jefferies and Leerink Partners

MapLight Therapeutics, a clinical-stage biopharmaceutical firm, has filed for an initial public offering. The Redwood City-based company's lead product candidate is a fixed-dose combination for schizophrenia and Alzheimer's disease psychosis. The treatment is in mid-stage trials, with results expected in the second half of next year. MapLight raised $372.5 million in a Series D financing in late July, valuing the company at $816 million. The IPO is being led by Morgan Stanley, Jefferies Financial Group, and Leerink Partners.

MapLight Therapeutics, a Redwood City-based biopharmaceutical company, has announced the initiation of a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of its investigational M1/M4 muscarinic agonist, ML-007C-MA, for the treatment of Alzheimer's disease psychosis (ADP). The Phase 2 VISTA study is a randomized, double-blind, placebo-controlled trial designed to enroll approximately 300 patients MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].

The study aims to assess the change in the Neuropsychiatric Inventory - Clinician Rating Scale Hallucinations and Delusions (NPI-C H+D) score from baseline to Week 7, with the primary endpoint being the efficacy of ML-007C-MA in reducing hallucinations and delusions associated with ADP. The trial is expected to provide results in the second half of next year, aligning with the company's mid-stage trial timeline MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].

MapLight Therapeutics' lead product candidate, ML-007C-MA, is a fixed-dose combination of the investigational M1/M4 muscarinic agonist, ML-007, and a peripherally acting anticholinergic (PAC). This formulation aims to activate both M1 and M4 muscarinic receptors in the central nervous system while mitigating peripheral cholinergic side effects MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].

The company recently raised $372.5 million in a Series D financing round, valuing it at $816 million. The initial public offering (IPO) is being led by Morgan Stanley, Jefferies Financial Group, and Leerink Partners. The IPO is expected to provide further funding for the development and commercialization of ML-007C-MA and other products in the pipeline MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].

Alzheimer's disease psychosis (ADP) is a serious neuropsychiatric complication of Alzheimer's disease (AD), affecting approximately 40% of individuals with AD. It is characterized by the presence of delusions and/or hallucinations and is associated with poorer patient outcomes, including faster cognitive and functional decline, higher rates of institutionalization, and increased mortality MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].

MapLight Therapeutics is focused on developing circuit-specific pharmacotherapies for debilitating central nervous system disorders, with a discovery platform that holds the potential to identify neural circuits causally linked to disease and target those circuits for therapeutic modulation MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis^[1].